Chudwin D S
Department of Immunology/Microbiology, Rush Medical College, Chicago, Illinois 60612.
Clin Immunol Immunopathol. 1989 Jan;50(1 Pt 1):62-71. doi: 10.1016/0090-1229(89)90222-5.
A mouse model was developed to test the efficacy of human immune globulin intravenous (IGIV) in prevention and treatment of pneumococcal bacteremia. Mice pretreated with IGIV and then challenged with types 3 or 7F Streptococcus pneumoniae had significantly increased (P less than 0.025) survival compared to controls. Three commercially available IGIV preparations were all effective in significantly increasing (P less than 0.025) survival in mice already infected. Mice treated with IGIV plus penicillin had significantly greater (P less than 0.05) survival than those who received penicillin alone. IGIV may be useful in treatment of pneumococcal bacteremia.
开发了一种小鼠模型来测试静脉注射人免疫球蛋白（IGIV）预防和治疗肺炎球菌菌血症的疗效。与对照组相比，预先用IGIV处理然后用3型或7F型肺炎链球菌攻击的小鼠存活率显著提高（P<0.025）。三种市售的IGIV制剂在显著提高（P<0.025）已感染小鼠的存活率方面均有效。用IGIV加青霉素治疗的小鼠比单独接受青霉素治疗的小鼠存活率显著更高（P<0.05）。IGIV可能对治疗肺炎球菌菌血症有用。
